FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W78262064> ?p ?o ?g. }

• W78262064 endingPage "1037" @default.
• W78262064 startingPage "1032" @default.
• W78262064 abstract "Abstract We report on a series of 26 patients diagnosed with primary (de novo) plasma cell (PC) leukemia (PCL) in whom we analyzed the clinicobiologic characteristics of the disease together with the immunophenotype, DNA cell content, proliferative index, and numeric chromosomal aberrations of the neoplastic PC, and compared them with 664 multiple myeloma (MM) patients at diagnosis. The median age, sex ratio, and bone lesion extension were similar, but PCL cases displayed a higher prevalence of clinical stage III, extramedullary involvement, and Bence Jones cases, with fewer IgA cases than for MM patients. In addition, according to several prognostic indicators (β2-microglobulin serum level, proportion of S-phase PCs, proteinuria, calcium serum level, lactate dehydrogenase [LDH] and renal function), the incidence of adverse prognostic factors was significantly higher in PCL versus MM. Immunophenotypic expression was similar for CD38, CD138, CD2, CD3, CD16, CD10, CD13, and CD15, but PCL differed from MM in the expression of CD56, CD9 HLA-DR, CD117, and CD20 antigens. Twenty-two PCL cases were diploid and one was hypodiploid, while most MM cases (57%) showed DNA hyperdiploidy. With the fluorescent in situ hydridization (FISH) technique, 12 of 13 PCL cases displayed the numeric aberrations, −13 (86%), ±1 (57%), +18 (43%), and −X in women (25%), but they lacked several numeric aberrations usually found in MM such as +3, +6, +9, +11, and +15. PCL cases had a lower overall response to therapy than MM cases (38% v 63%, P = .01332). Among PCL patients, a trend for a worse response was observed in cases treated with melphalan and prednisone (MP) versus polychemotherapy. Overall survival was significantly worse in PCL versus MM patients (8 v 36 months,P &lt; .0001), but it was significantly better in PCL patients treated with polychemotherapy versus MP (18 v 3 months,P = .0137). By contrast, MM patients did not show significant differences in overall survival according to the treatment used, MP or polychemotherapy. Ten variables seemed to predict survival in PCL patients, but only the β2-microglobulin level and S-phase PCs retained an independent value in multivariate analysis. In summary, our study illustrates that PCs from PCL display singular phenotypic, DNA cell content, and cytogenetic characteristics that lead to a different disease evolution versus MM." @default.
• W78262064 created "2016-06-24" @default.
• W78262064 creator A5007471850 @default.
• W78262064 creator A5009207655 @default.
• W78262064 creator A5017341923 @default.
• W78262064 creator A5020702876 @default.
• W78262064 creator A5031837957 @default.
• W78262064 creator A5039056346 @default.
• W78262064 creator A5057506884 @default.
• W78262064 creator A5057834186 @default.
• W78262064 creator A5059482051 @default.
• W78262064 creator A5076175726 @default.
• W78262064 creator A5088409474 @default.
• W78262064 date "1999-02-01" @default.
• W78262064 modified "2023-10-17" @default.
• W78262064 title "Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics" @default.
• W78262064 cites W120865734 @default.
• W78262064 cites W1505185876 @default.
• W78262064 cites W1524905787 @default.
• W78262064 cites W1595511347 @default.
• W78262064 cites W163040189 @default.
• W78262064 cites W1872098847 @default.
• W78262064 cites W1944291718 @default.
• W78262064 cites W1971367127 @default.
• W78262064 cites W1971636731 @default.
• W78262064 cites W1985170347 @default.
• W78262064 cites W1989169182 @default.
• W78262064 cites W2006382315 @default.
• W78262064 cites W2025547081 @default.
• W78262064 cites W2029070213 @default.
• W78262064 cites W2054970678 @default.
• W78262064 cites W2068026063 @default.
• W78262064 cites W2071815761 @default.
• W78262064 cites W2087869106 @default.
• W78262064 cites W2105844501 @default.
• W78262064 cites W2113424017 @default.
• W78262064 cites W2116216500 @default.
• W78262064 cites W2129856600 @default.
• W78262064 cites W2142188119 @default.
• W78262064 cites W2170918668 @default.
• W78262064 cites W4253849740 @default.
• W78262064 cites W68080126 @default.
• W78262064 doi "https://doi.org/10.1182/blood.v93.3.1032" @default.
• W78262064 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9920853" @default.
• W78262064 hasPublicationYear "1999" @default.
• W78262064 type Work @default.
• W78262064 sameAs 78262064 @default.
• W78262064 citedByCount "276" @default.
• W78262064 countsByYear W782620642012 @default.
• W78262064 countsByYear W782620642013 @default.
• W78262064 countsByYear W782620642014 @default.
• W78262064 countsByYear W782620642015 @default.
• W78262064 countsByYear W782620642016 @default.
• W78262064 countsByYear W782620642017 @default.
• W78262064 countsByYear W782620642018 @default.
• W78262064 countsByYear W782620642019 @default.
• W78262064 countsByYear W782620642020 @default.
• W78262064 countsByYear W782620642021 @default.
• W78262064 countsByYear W782620642022 @default.
• W78262064 countsByYear W782620642023 @default.
• W78262064 crossrefType "journal-article" @default.
• W78262064 hasAuthorship W78262064A5007471850 @default.
• W78262064 hasAuthorship W78262064A5009207655 @default.
• W78262064 hasAuthorship W78262064A5017341923 @default.
• W78262064 hasAuthorship W78262064A5020702876 @default.
• W78262064 hasAuthorship W78262064A5031837957 @default.
• W78262064 hasAuthorship W78262064A5039056346 @default.
• W78262064 hasAuthorship W78262064A5057506884 @default.
• W78262064 hasAuthorship W78262064A5057834186 @default.
• W78262064 hasAuthorship W78262064A5059482051 @default.
• W78262064 hasAuthorship W78262064A5076175726 @default.
• W78262064 hasAuthorship W78262064A5088409474 @default.
• W78262064 hasConcept C126322002 @default.
• W78262064 hasConcept C142724271 @default.
• W78262064 hasConcept C147483822 @default.
• W78262064 hasConcept C18031839 @default.
• W78262064 hasConcept C196166836 @default.
• W78262064 hasConcept C203014093 @default.
• W78262064 hasConcept C2776364478 @default.
• W78262064 hasConcept C2779338263 @default.
• W78262064 hasConcept C2780353925 @default.
• W78262064 hasConcept C71924100 @default.
• W78262064 hasConcept C90924648 @default.
• W78262064 hasConceptScore W78262064C126322002 @default.
• W78262064 hasConceptScore W78262064C142724271 @default.
• W78262064 hasConceptScore W78262064C147483822 @default.
• W78262064 hasConceptScore W78262064C18031839 @default.
• W78262064 hasConceptScore W78262064C196166836 @default.
• W78262064 hasConceptScore W78262064C203014093 @default.
• W78262064 hasConceptScore W78262064C2776364478 @default.
• W78262064 hasConceptScore W78262064C2779338263 @default.
• W78262064 hasConceptScore W78262064C2780353925 @default.
• W78262064 hasConceptScore W78262064C71924100 @default.
• W78262064 hasConceptScore W78262064C90924648 @default.
• W78262064 hasIssue "3" @default.
• W78262064 hasLocation W782620641 @default.
• W78262064 hasOpenAccess W78262064 @default.
• W78262064 hasPrimaryLocation W782620641 @default.

• next